GHP names energy exec as new president and CEO

taking the lead

Steve Kean will transition from leading Kinder Morgan to assuming the role of president and CEO of the Greater Houston Partnership later this year. Photo courtesy of the GHP

A longtime energy executive has been named the next president and CEO of the Greater Houston Partnership. He'll take on the new role this fall.

The GHP named Steve Kean, who currently serves as the CEO of Kinder Morgan Inc., to the position. He's expected to transition from CEO to board of directors member at Kinder Morgan on August 1. Kean will then assume his new position at GHP no later than Dec. 1.

Dr. Marc L. Boom, GHP board chair and president and CEO of Houston Methodist, made the announcement at a press conference June 21.

“Steve brings incredible business acumen and leadership skills to the organization," Boom says in a statement. "Coupled with an extraordinary passion for Houston, he will build on the Partnership’s momentum to continue to advance greater Houston as a region of extraordinary growth and opportunity.”

The GHP's outgoing president and CEO, Bob Harvey, announced his retirement earlier this year, and will remain in his position until Kean is onboarded. Kean was selected via a search committee established by 2022 board chair, Thad Hill. The committee was chaired by Marc Watts and included Boom, Thad Hill, Paul Hobby, Gina Luna, Eric Mullins, Armando Perez, and Ruth Simmons. The process, which looked at over 70 highly-qualified Houston leaders, also included the services of Spencer Stuart to manage the search.

“This last decade has been a dynamic time for Houston and the Partnership," Harvey says in a statement. "As a life-long Houstonian, it has been an honor to focus my efforts on supporting Houston’s continued growth and working with the business community to create opportunities for all Houstonians. This is an exciting time for Houston. I am very pleased that Steve is enthusiastic about leading the Partnership, and I look forward to the organization’s continued success under his leadership.”

With decades in the energy industry, Kean joined Kinder Morgan in 2002 and has served as COO, president of Natural Gas Pipelines, and president of Kinder Morgan Inc. before rising to CEO. He received a bachelor's degree from Iowa State University and his law degree from the University of Iowa.

“I’m grateful for the opportunity to serve our region in this role," he says. "I look forward to building on what Bob, the Board, members, and staff of the Partnership have accomplished. I know first-hand the opportunities that a vibrant business sector can create for people and communities. I look forward to expanding those opportunities further.”

From Your Site Articles
Houston Methodist has been recognized in two different awards programs. Courtesy of Methodist Hospital/Facebook

Houston hospital system recognized for patient care and technology

Industry standard

Houston Methodist has a couple new feathers in its cap. The hospital system was recognized with two different awards recently.

Houston Methodist was the only hospital system to have four hospitals receive a 2019 Vizient Bernard A. Birnbaum, M.D., Quality Leadership Award, a recognition that praises hospitals for demonstrating quality and care. The Vizient Quality and Accountability Study has been conducted every year since 2005.

Houston Methodist Hospital was recognized in the in the comprehensive academic medical center category, Houston Methodist Sugar Land received an award in the specialized complex care medical center category, and both Houston Methodist Willowbrook and Houston Methodist The Woodlands were selected for the complex medical center category.

"Having four of our hospitals on this list is extraordinary. Receiving such national recognition is an honor, but I'm most proud that the reason for these awards is our concerted focus on quality patient care," says Marc L. Boom, president and CEO of Houston Methodist, in a news release.

This year was slightly different from years prior, and 349 participating hospitals were divided into four cohorts for the Vizient Quality and Accountability Ranking. Among some of the assets considered were safety, mortality, clinical effectiveness, efficiency and patient centeredness. The announcement was made last week during the 2019 Vizient Connections Education Summit in Las Vegas.

Meanwhile, the hospital system was also recently recognized for being among the "Most Wired" in the United States. For the 12th consecutive year, Houston Methodist received the 2019 HealthCare's Most Wired recognition from the College of Healthcare Information Management Executives, or CHiME. The award recognizes hospital systems for their innovation, adoption, and optimal use of information technology.

New this year was CHiME's ambulatory facilities recognition, which Houston Methodist received for outstanding technical accomplishments, earning a Certified Level 8 Quality Award.

Innovation has an increased focus at Houston Methodist since premiering its Center for Innovation — a group of leaders charged with finding new technologies for the hospital system for patients, physicians, and staff — under the leadership of Roberta Schwartz. She is the system's executive vice president, chief innovation officer, and chief executive officer of Houston Methodist Hospital.

After 17 years at Houston Methodist, Schwartz says she's seen the evolution of tech and is taking note of where the industry is going.

"I think we're an industry that is transforming itself. We're either going to be disrupted or we're going to do the disruption ourselves," Schwartz tells InnovationMap in a previous article. "There's nobody who knows health care better than we do, so if we're going to transform the industry, I want that transformation to come from the inside."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston space company lands latest NASA deal to advance lunar logistics

To The Moon

Houston-based space exploration, infrastructure, and services company Intuitive Machines has secured about $2.5 million from NASA to study challenges related to carrying cargo on the company’s lunar lander and hauling cargo on the moon. The lander will be used for NASA’s Artemis missions to the moon and eventually to Mars.

“Intuitive Machines has been methodically working on executing lunar delivery, data transmission, and infrastructure service missions, making us uniquely positioned to provide strategies and concepts that may shape lunar logistics and mobility solutions for the Artemis generation,” Intuitive Machines CEO Steve Altemus says in a news release.

“We look forward to bringing our proven expertise together to deliver innovative solutions that establish capabilities on the [moon] and place deeper exploration within reach.”

Intuitive Machines will soon launch its lunar lander on a SpaceX Falcon 9 rocket to deliver NASA technology and science projects, along with commercial payloads, to the moon’s Mons Mouton plateau. Lift-off will happen at NASA’s Kennedy Space Center in Florida within a launch window that starts in late February. It’ll be the lander’s second trip to the moon.

In September, Intuitive Machines landed a deal with NASA that could be worth more than $4.8 billion.

Under the contract, Intuitive Machines will supply communication and navigation services for missions in the “near space” region, which extends from the earth’s surface to beyond the moon.

The five-year deal includes an option to add five years to the contract. The initial round of NASA funding runs through September 2029.

Play it back: Houston home tech startup begins 2025 with fresh funding

HOUSTON INNOVATORS PODCAST EPISODE 272

One of the dozen or so Houston startups kicking of the new year with fresh funding is SmartAC.com, a company that's designed a platform that enables contractors in the HVAC and plumbing industries to monitor, manage, and optimize their maintenance memberships through advanced sensors, AI-driven diagnostics, and proactive alerts.

Last month, the SmartAC.com raised a follow-on round with support from local investor Mercury to continue growth and expansion of the product, which has evolved on many ways since the company launched in 2020, emerging from stealth with $10 million raised in a series A. In a May 2023 interview for the Houston Innovators Podcast, Founder and CEO Josh Teekell explained how he embraced the power of a pivot.

The company's sensors can monitor all aspects of air conditioning units and report back any issues, meaning homeowners have quicker and less costly repairs. While SmartAC.com started with providing the service and tech to homeowners directly, Teekell says he's had a greater interest in working with plumbers and HVAC companies who then deploy the technology to their customers.

"It became quite evident that homeowners don't care about air conditioning really at all until their system breaks," Teekell says on the show. "The technology is really built around giving those contractors as another way to gain a customer relationship and keep it."

Revisit the podcast episode below where Teekell talks about SmartAC.com's last raise.

SmartAC.com's previous round in 2023 — a $22 million series B — was used grow its team that goes out to deploy the technology and train the contractors on the platform.

"We've been very fortunate to get some of the biggest names in Houston on our cap table," Teekell says in the May 2023 conversation. "Since we're raising a bunch of money locally, everyone understands what a pain air conditioning can be."

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

View All Listings